Tocilizumab for severe COVID-19 pneumonia – Authors' reply-Reference-Cited by-同舟云学术

Tocilizumab for severe COVID-19 pneumonia – Authors' reply

Published:2020-11 Issue:11 Volume:2 Page:e660-e661
ISSN:2665-9913
Container-title:The Lancet Rheumatology
language:en
Short-container-title:The Lancet Rheumatology

Author:

Guaraldi Giovanni,Meschiari Marianna,Milic Jovana,Cozzi-Lepri Alessandro,Mussini Cristina

Publisher

Elsevier BV

Subject

Immunology,Immunology and Allergy,Rheumatology

Reference5 articles.

1. Tocilizumab in patients with severe COVID-19: a retrospective cohort study;Guaraldi;Lancet Rheumatol,2020

2. Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia;McGonagle;Lancet Rheumatol,2020

3. Marked T cell activation, senescence, exhaustion and skewing towards TH17 in patients with COVID-19 pneumonia;De Biasi;Nat Comm,2020

4. Machine learning in predicting respiratory failure in patients with COVID-19 pneumonia—challenges, strengths, and opportunities in a global health emergency;Ferrari;medRxiv,2020

5. A second chance to get causal inference right: a classification of data science tasks;Hernán;Chance,2019

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Even one dose of tocilizumab could hinder bad prognosis of cytokines storm in COVID-19 patients;Cytokine;2024-01

2. Tocilizumab for the treatment of COVID-19;Expert Review of Anti-infective Therapy;2023-06-19

3. The Frequency and the character of bacterial infection in patients with COVID-19;South Russian Journal of Therapeutic Practice;2023-03-28

4. The effectiveness of Tocilizumab in severe covid 19 pneumonia among critically ill patients;Research Journal of Pharmacy and Technology;2023-02-28

5. Efficacy of tocilizumab therapy in severe COVID-19 pneumonia patients and determination of the prognostic factors affecting 30 days mortality;Marmara Medical Journal;2022-10-31